Stockscreener 앱 받기
273.55
5.46%
14.16
시간 외 거래:
273.55
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - BioSpace
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference | ALNY Stock News - GuruFocus
Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Target Price Raised by UBS | ALNY Stock News - GuruFocus
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - TradingView
UBS Boosts Alnylam (ALNY) Price Target Amid Promising Early Launch Trends | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Ch - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating - marketscreener.com
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight - GuruFocus
Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo
Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlig - GuruFocus
Alnylam: Q1 Earnings Snapshot - MySA
Alnylam Earnings: Launch of Amvuttra for ATTR-CM Underway; Fair Value Up to $245 From $223 - Morningstar
Narrow-Moat Alnylam's Strong Patient Uptake Drives Growth; Diverse Pipeline Makes Progress - Morningstar
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia - Seeking Alpha
Alnylam Pharmaceuticals Reports Strong Start to 2025 - TipRanks
Alnylam Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Alnylam (ALNY): Price Target Raised Amid Promising Amvuttra Laun - GuruFocus
Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2025 Growth - GuruFocus
Alnylam Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Alnylam Q1 2025 beats EPS forecast, stock drops - Investing.com India
Alnylam Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Alnylam Q1 2025 slides: 28% revenue growth as AMVUTTRA drives TTR franchise expansion - Investing.com
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises - marketscreener.com
ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet - simplywall.st
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe - simplywall.st
Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha
European Regulators Endorse Breakthrough ATTR-CM Treatment as Alnylam Hits All 10 Trial Endpoints - Stock Titan
Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency - marketscreener.com
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Tr - GuruFocus
Alnylam (ALNY) Secures EMA Committee Support for Expanded Use of Vutrisiran | ALNY Stock News - GuruFocus
Alnylam’s vutrisiran gets positive CHMP opinion for ATTR-CM - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Alnylam (ALNY) Gains Positive CHMP Opinion for Amvuttra Label Ex - GuruFocus
1.07%
0.63%
자본화:
|
볼륨(24시간):